Brain local delivery strategy

Raju, S.; Sathe, Priyadarshini; Khan, Wahid

doi:10.1016/b978-0-12-814001-7.00011-1

Cited by 8 publications

(6 citation statements)

References 167 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…CED is based on the infusion of fluids under pressure into the brain parenchyma through stereotactically placed catheters. The distribution of compounds attained is broader because it is facilitated by convective flow and not merely diffusion [185,186]. Critical parameters to consider during CED include volume of the infusate, duration of infusion, placement of the catheter and catheter design [187].…”

Section: Convection-enhanced Deliverymentioning

confidence: 99%

The influence of the blood–brain barrier in the treatment of brain tumours

et al. 2022

View full text Add to dashboard Cite

Brain tumours have a poor prognosis and lack effective treatments. The blood-brain barrier (BBB) represents a major hurdle to drug delivery to brain tumours. In some locations in the tumour, the BBB may be disrupted to form the blood-brain tumour barrier (BBTB). This leaky BBTB enables diagnosis of brain tumours by contrast enhanced magnetic resonance imaging; however, this disruption is heterogeneous throughout the tumour. Thus, relying on the disrupted BBTB for achieving effective drug concentrations in brain tumours has met with little clinical success. Because of this, it would be beneficial to design drugs and drug delivery strategies to overcome the 'normal' BBB to effectively treat the brain tumours. In this review, we discuss the role of BBB/BBTB in brain tumour diagnosis and treatment highlighting the heterogeneity of the BBTB. We also discuss various strategies to improve drug delivery across the BBB/BBTB to treat both primary and metastatic brain tumours. Recognizing that the BBB represents a critical determinant of drug efficacy in central nervous system tumours will allow a more rapid translation from basic science to clinical application. A more complete understanding of the factors, such as BBB-limited drug delivery, that have hindered progress in treating both primary and metastatic brain tumours, is necessary to develop more effective therapies.

show abstract

Section: Convection-enhanced Deliverymentioning

confidence: 99%

The influence of the blood–brain barrier in the treatment of brain tumours

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Most of the time, the drug and drug carrier are administered orally and intravenously. While tailored nanodrug carriers can gain the ability to target and cross the blood–brain barrier, these drugs need to pass through the systemic circulation, and the drug will always reach other organs, leading to toxicity–especially when patients are severely ill and require large doses [ 75 ]. Therefore, by changing the drug delivery strategy, such as the use of local administration, it is possible to bypass the BBB and deliver drugs directly in the brain ( Figure 3 c).…”

Section: Strategies For Passing Through the Blood–brain Barriermentioning

confidence: 99%

“…The majority of the nanoparticles targeting the brain are administered either intravenously or orally, resulting in some amount of drug reaching other organs and leading to toxicity [ 75 ]. Local administration to the GBM has several advantages over systemic administration, such as bypassing the BBB and increasing the bioavailability of the therapeutic agent at the tumor site without causing systemic toxicity [ 76 , 77 ].…”

Section: Strategies For Passing Through the Blood–brain Barriermentioning

confidence: 99%

Novel Nano-Drug Delivery System for Brain Tumor Treatment

Qiu

et al. 2022

Cells

View full text Add to dashboard Cite

As the most dangerous tumors, brain tumors are usually treated with surgical removal, radiation therapy, and chemotherapy. However, due to the aggressive growth of gliomas and their resistance to conventional chemoradiotherapy, it is difficult to cure brain tumors by conventional means. In addition, the higher dose requirement of chemotherapeutic drugs caused by the blood–brain barrier (BBB) and the untargeted nature of the drug inevitably leads to low efficacy and systemic toxicity of chemotherapy. In recent years, nanodrug carriers have attracted extensive attention because of their superior drug transport capacity and easy-to-control properties. This review systematically summarizes the major strategies of novel nano-drug delivery systems for the treatment of brain tumors in recent years that cross the BBB and enhance brain targeting, and compares the advantages and disadvantages of several strategies.

show abstract

“…CED primarily utilizes bulk flow, and diffusion is a minor component. While diffusion relies on the concentration gradient, and macromolecules penetrate only up to a few millimeters under diffusive forces, the distribution pattern attained with CED can be described by Darcy’s law, in which the velocity of the molecule is dependent on the pressure gradient and hydraulic conductivity of the medium [ 81 , 82 ].…”

Section: Invasive Technologiesmentioning

confidence: 99%

Addressing BBB Heterogeneity: A New Paradigm for Drug Delivery to Brain Tumors

et al. 2020

View full text Add to dashboard Cite

Effective treatments for brain tumors remain one of the most urgent and unmet needs in modern oncology. This is due not only to the presence of the neurovascular unit/blood–brain barrier (NVU/BBB) but also to the heterogeneity of barrier alteration in the case of brain tumors, which results in what is referred to as the blood–tumor barrier (BTB). Herein, we discuss this heterogeneity, how it contributes to the failure of novel pharmaceutical treatment strategies, and why a “whole brain” approach to the treatment of brain tumors might be beneficial. We discuss various methods by which these obstacles might be overcome and assess how these strategies are progressing in the clinic. We believe that by approaching brain tumor treatment from this perspective, a new paradigm for drug delivery to brain tumors might be established.

show abstract

Brain local delivery strategy

Cited by 8 publications

References 167 publications

The influence of the blood–brain barrier in the treatment of brain tumours

The influence of the blood–brain barrier in the treatment of brain tumours

Novel Nano-Drug Delivery System for Brain Tumor Treatment

Addressing BBB Heterogeneity: A New Paradigm for Drug Delivery to Brain Tumors

Contact Info

Product

Resources

About